VIII

AAV5 DetectCDx™ Kit Is First ARUP Test Developed to Support a New Therapy

Retrieved on: 
Tuesday, September 27, 2022
ARUP Laboratories, VIII, Laboratory, Factor VIII, Cdx, MD, SALT, University, Haemophilia, European Commission, Experimental pathology, BioMarin Pharmaceutical, CMA, Clinical trial, Partnership, Patient, CE, Hercules, Doctor of Philosophy, ARUP, BLA, European Commission–AstraZeneca COVID-19 vaccine dispute, Royal commission, Union, Multimedia, Medical device, Pharmaceutical industry, EU, Pathology

The AAV5 DetectCDx Kit was developed by ARUP Laboratories' PharmaDx Group in partnership with BioMarin.

Key Points: 
  • The AAV5 DetectCDx Kit was developed by ARUP Laboratories' PharmaDx Group in partnership with BioMarin.
  • The AAV5 DetectCDx Kit was developed by ARUP Laboratories' PharmaDx Group in partnership with BioMarin to help identify patients who are eligible for treatment with ROCTAVIAN.
  • The AAV5 DetectCDx Kit is already authorized for use in Europe, having received its Conformit Europenne (CE) mark in January 2022.
  • When clinicians begin using the AAV5 DetectCDx Kit, the companion diagnostic will become the first ARUP-developed test to be used in Europe.

Global Hemophilia Gene Therapy Market 2022: Advantages Over Traditional Treatments Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 21, 2022
Genetics, Pharmaceutical, Health, VIII, Linear code, Muscle, IX, Platelet, Risk, FDA, Food, XI, Spark Therapeutics, BioMarin Pharmaceutical, Ultragenyx, Intracranial hemorrhage, Industry, Haemophilia, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Region, Protein, Haemophilia B, US, Marketing, Gene expression, Joint, Pfizer, Plasma, CAGR, Medical device, Birth control, Gland

The "Hemophilia Gene Therapy Market, by Hemophilia Type, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hemophilia Gene Therapy Market, by Hemophilia Type, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • As against conventional clotting factor replacement therapy, gene therapy is expected to offer sustainable cure for hemophilia by correcting defective gene sequence (F8 or F9 gene) that codes for clotting factor VIII or IX in the patient's body.
  • There is dose dependent gene expression level observed which means genetic expression for clotting factor increases with increased dose of gene therapy.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
    The global hemophilia gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
    Detailed Segmentation: Global Hemophilia Gene Therapy Market, By Hemophilia Type:
    Global Hemophilia Gene Therapy Market, By Region:

Sernova to Present at H.C. Wainwright Annual Global Investment Conference and LifeSci Partners HealthTech Symposium

Retrieved on: 
Thursday, September 8, 2022
University, Conditional sentence, Haemophilia, Technology, Cell, Survival, Potency (pharmacology), Protein, Regenerative medicine, Type 1 diabetes, Degenerative disease, VIII, Immune system, Diabetes, Thyroid disease, Chicago (franchise), Trial of the century, Patient, Thyroid, Online shopping, Pharmaceutical industry

Details of the events can also be found on the events page of the Sernova website at https://www.sernova.com/investor/?disclaimer=1#Events .

Key Points: 
  • Details of the events can also be found on the events page of the Sernova website at https://www.sernova.com/investor/?disclaimer=1#Events .
  • If interested in arranging a 1x1 meeting request at the H.C. Wainwright conference, please contact the conference organizers.
  • In May 2022, Sernova and Evotec entered into a global strategic collaboration to develop an implantable off-the-shelf iPSC-based (induced pluripotent stem cells) beta cell replacement therapy.
  • This collaboration potentially provides Sernova an unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2).

Sernova Announces the Appointment of Daniel Mahony, Ph.D. to its Board of Directors

Retrieved on: 
Wednesday, September 7, 2022
Health care, Conditional sentence, Haemophilia, Barings Bank, Technology, Wellcome Sanger Institute, Cell, Survival, Research, FSE, Potency (pharmacology), University of Cambridge, Protein, Morgan Stanley, Regenerative medicine, Type 1 diabetes, Board, Degenerative disease, TSX, Association, BIA, GLOBE, Board of directors, Biotechnology, Therapy, Polar Capital Technology Trust, Doctor of Philosophy, Immune system, VIII, University of Oxford, PSH, Biochemistry, Diabetes, Thyroid disease, University, Chicago (franchise), Evotec, Trial of the century, Patient, Thyroid, Pharmaceutical industry, Management, Director

LONDON, Ontario, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced the appointment of Daniel Mahony, Ph.D. to its Board of Directors, effective September 30th, 2022. Dr. Mahony is Entrepreneur-in-Residence at Evotec and is also responsible for managing Evotec’s equity investment portfolio.

Key Points: 
  • We are delighted to welcome Dr. Mahony to Sernovas Board of Directors, said Frank Holler, Executive Chair of Sernova.
  • This background gives him deep insights into the healthcare business and capital markets which will be very valuable for Sernova.
  • Dr. Mahony stated, Sernova is uniquely well positioned with its Cell Pouch System to become a leading player in regenerative medicine.
  • This collaboration potentially provides Sernova an unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2).

Footprint and Gores Holdings VIII, Inc. Announce Continued Momentum in Business, Additional Capital to Fund Business Plan and Strategic Revision of Transaction Terms

Retrieved on: 
Tuesday, September 6, 2022
Chemicals, Plastics, Recycling, Environment, Manufacturing, CEO, Technology, Prospectus, Securities Act of 1933, Sweetgreen, Proxy, Plastic, PAE, U.S. Securities and Exchange Commission, CO2, LLC, Risk, Communication, Intel, Walmart, Time, Sale, Kraft Foods, Board, Albertsons, SEC, Nasdaq, VIII, The Gores Group, Holding, Food chain, Conagra Brands, Industry, Registration statement, Food, NASDAQ, Solution, CNBC, Atmosphere, PIPE, Reading, Investment, Water, Special, Hostess, Koch, Private Securities Litigation Reform Act, Acquisition, Growth, Review, Trust, Register, Person, Union, Goal, United Wholesale Mortgage, Attention, Form, Failure, Name, Procter & Gamble, Forward-looking statement, Renewable energy, Management, Bottled water, Security (finance), Risk management, Audit, Footprint, Polestar

In connection with the updated transaction, Footprint secured an approximately $300 million standby equity facility available upon the closing of the transaction.

Key Points: 
  • In connection with the updated transaction, Footprint secured an approximately $300 million standby equity facility available upon the closing of the transaction.
  • Additionally, Footprint has received approval for an initial $280 million facility to fund equipment purchases through the end of 2023.
  • To date, affiliates of The Gores Group have announced or closed ten business combinations representing approximately $60 billion in transaction value which include: Hostess (Gores Holdings, Inc.), Verra Mobility (Gores Holdings II, Inc.), PAE (Gores Holdings III, Inc.), Luminar (Gores Metropoulos, Inc.), United Wholesale Mortgage (Gores Holdings IV, Inc.), Ardagh Metal Packaging (Gores Holdings V, Inc.), Matterport (Gores Holdings VI, Inc.), Sonder (Gores Metropoulos II, Inc.), Polestar (Gores Guggenheim) and Footprint (pending; Gores Holdings VIII, Inc.).
  • Neither Gores Holdings VIII nor Footprint gives any assurance that either Gores Holdings VIII or Footprint will achieve its expectations.

Sernova Receives Second Tranche Equity Investment from Evotec of $6.8 Million at a Price of $2.50 Per Share

Retrieved on: 
Thursday, September 1, 2022
University, Conditional sentence, Haemophilia, CEO, Technology, Cell, Survival, Potency (pharmacology), IPSC, NASDAQ, Protein, Exercise, Regenerative medicine, Type 1 diabetes, EVO, Degenerative disease, FSE, TSX, Indian stock exchange, GLOBE, VIII, Company, Therapy, Immune system, PSH, Diabetes, Thyroid disease, Hypothyroidism, Chicago (franchise), Evotec, Trial of the century, Patient, Thyroid, Pharmaceutical industry

Upon completion of the second tranche, Evotecs strategic investment in Sernova totals $27,098,000.

Key Points: 
  • Upon completion of the second tranche, Evotecs strategic investment in Sernova totals $27,098,000.
  • Evotecs investment at $2.50 per share, significantly more than double yesterdays closing price, reflects the value our strategic partner places on Sernova relative to the current trading price on the TSX, commented Dr. Philip Toleikis, President and CEO of Sernova Corp.
  • The dedication and synergy of our mutual teams to advance the iPSC diabetes program expeditiously has been impressive.
  • In May 2022, Sernova and Evotec entered into a global strategic collaboration to develop an implantable off-the-shelf iPSC-based (induced pluripotent stem cells) beta cell replacement therapy.

Acquired Hemophilia Treatment Global Market Report 2022: Focus on Product Pipeline Remains the Key Focus Among Market Players - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 30, 2022
Health, Pharmaceutical, Patient, Haemophilia, Ageing, National Organization for Rare Disorders, NORD, Medicine, Incidence, National Organization of Short Statured Adults, Intelligence, DDAVP, Hospital, Factor VIII, VII, VIII, CAGR, Population, Bleeding, APCC, Degenerative disease, Efficiency, Renewable energy, Medical imaging, Healthcare

The "Acquired Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acquired Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Medical practitioners warn that acquired hemophilia can cause life-threatening bleeding complications in severe cases.
  • The acquired hemophilia treatment market is anticipated to grow at a CAGR of 3.25% during the forecast period of 2022-2030.
  • After scrutiny of the global acquired hemophilia treatment market, the regional trends, market sizes, and the overall growth paired with the latest and anticipated events, North America is observed to be the most dominant regional market for acquired hemophilia treatment.

Redwire’s Critical Imaging and Navigation Technology Launching on NASA’s Historic Artemis I Mission to the Moon

Retrieved on: 
Thursday, August 25, 2022
Satellite, Software, Hardware, Engineering, Technology, Aerospace, Manufacturing, Other Technology, COO, Technology, Camera control unit, Photogrammetry, NYSE, Artemis 2, Kennedy Space Center, Airbus, Spacecraft, NASA, Redwire, European Service Module, Lockheed Martin, Science, Corporation, GPS, CSS, RDW, VIII, Electronics, III, Artemis program, Artemis, ESM, Communications satellite, Moon, Mars

Our technical contributions to this historic mission are emblematic of the innovation and strength of the American industrial supply base that anchors our nations space program.

Key Points: 
  • Our technical contributions to this historic mission are emblematic of the innovation and strength of the American industrial supply base that anchors our nations space program.
  • Redwire technology has supported over 50 years of NASA exploration and we are excited to build on that legacy in this new era of discovery.
  • Redwire is providing an array of internal and external inspection and navigation cameras comprising the Orion Camera System, under a contract with Lockheed Martin.
  • CSS technology is currently providing critical navigation capability on GPS, NASAs Lucy mission to Jupiters Trojan asteroids, NASAs IXPE mission to observe black holes and neutron stars and NOAAs GOES platforms for Earth weather monitoring.

Possible Link Between COVID-19 Vaccination and Autoimmune Disorders: Investigation by NCKU Researchers

Retrieved on: 
Wednesday, August 3, 2022
VIII, Diagnosis, COVID-19, Physician, History, Degenerative disease, Patient, National Cheng Kung University Hospital, Literature, Haemophilia, Disease, Causality, Vaccine, Journal, Autoimmune disease, Severe acute respiratory syndrome coronavirus 2, RNA transfection, AHA, Mortality, Immune system, Association, Awareness, Risk, Pfizer

Ya Ting Hsu and Dr. Peng Chan Lin of the NCKU Hospital, Taiwan, have recently reported a case that points towards such a possibility.

Key Points: 
  • Ya Ting Hsu and Dr. Peng Chan Lin of the NCKU Hospital, Taiwan, have recently reported a case that points towards such a possibility.
  • For example, do patients with known autoimmune diseases have a higher risk of developing vaccine-related autoimmune disease?
  • Besides reporting their case, the researchers studied existing literature and identified six other vaccine-related cases of AHA reported since 2021.
  • These findings point to a possible association between SARS-CoV-2 mRNA vaccines and autoimmune diseases like AHA.

LFB Announces the Approval of CEVENFACTA® (eptacog beta) in the European Union

Retrieved on: 
Monday, July 25, 2022
Science, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Genetics, Clinical Trials, Anticoagulant, LFB, Bleeding, VIII, BU, EMA, European Medicines Agency, Patient, Pharmaceutical industry

LFB today announced that the European Medicines Agency (EMA) has granted on July 15th a Marketing Authorisation for CEVENFACTA (eptacog beta), as the first new bypassing agent in over 20 years.

Key Points: 
  • LFB today announced that the European Medicines Agency (EMA) has granted on July 15th a Marketing Authorisation for CEVENFACTA (eptacog beta), as the first new bypassing agent in over 20 years.
  • Denis Delval, LFBs Chairman and Chief Executive Officer, stated: We are very pleased with the approval of CEVENFACTA by the EMA, which provides a new treatment option for haemophilia patients with inhibitors in the European Union.
  • This approval is a validation of our innovative LFB technology and the acknowledgement of LFBs deep commitment to patients.
  • The approval of CEVENFACTA was based on data from the phase III clinical trials, PERSEPT 1 and PERSEPT 3.